Comparative Pharmacology
Head-to-head clinical analysis: NITROUS OXIDE USP versus ULTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROUS OXIDE USP versus ULTANE.
NITROUS OXIDE, USP vs ULTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
Sevoflurane is a volatile general anesthetic that enhances inhibitory neurotransmission via GABA-A and glycine receptors, and inhibits excitatory neurotransmission via NMDA and nicotinic acetylcholine receptors, producing anesthesia, amnesia, and muscle relaxation.
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
Inhalation: Induction, 0.5-3% sevoflurane in oxygen or oxygen/nitrous oxide; maintenance, 1.5-3% sevoflurane with or without nitrous oxide.
None Documented
None Documented
Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination.
Terminal elimination half-life of inorganic fluoride is approximately 2-5 hours (mean 3.0 h) in adults; context: prolonged with obesity or renal impairment.
Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination.
Renal excretion of inorganic fluoride metabolites accounts for >95% of elimination; <5% excreted unchanged in urine.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic